Tag: Cancer Biomarker

Categories

Webinar: Unique, Early Biomarker for Cell Proliferation

by Eagle Biosciences

 

Eagle Biosciences and AroCell are pleased to invite you to a
webinar on the application of the TK
210 (Thymidine Kinase 1) ELISA in the study of malignancies.

There are many biomarkers of tumor mass, but few serum
biomarkers of tumor proliferation, a key indicator when making prognoses
and choosing and monitoring therapy.

The assay of serum Thymidine Kinase 1 with the AroCell TK 210
ELISA has the potential to be such a biomarker. There is no cost for
this event.

 

When: March
23, 2017 | 11 am to 11:30 am EDT

Presenters:

  • Staffan Eriksson, Professor in Medical and Physiological Chemistry, Swedish
    University of Agricultural Sciences
  • Martin
    Shaw    , Business Development Manager at AroCell.

Key points of the presentation will be:

  • Thymidine
    kinase 1 (TK1) is a well-known proliferation biomarker but most
    current methods are based on enzyme activity methods and may
    underestimate serum TK1 levels, particularly in subjects with solid
    tumors
  • The AroCell
    TK 210 ELISA adds value to studies with existing tumor biomarkers
  • Data will be
    presented on the value of the AroCell TK 210 ELISA in the study of a
    range of hematological and solid tumors.

Receive a white paper on the use of TK1 and the AroCell TK210 ELISA in studying solid tumors HERE

 

 

About AroCell

AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.
Categories

Unique, Early Biomarker for Cell Proliferation

by Eagle Biosciences

Introducing the TK 210 ELISA assay kit from AroCell, the most sensitive assay available for measuring Thymadine Kinase 1 (TK1). TK1 is a key enzyme in DNA replication and it is up-regulated in proliferating cells. Many studies have shown it to be a valuable cancer biomarker but most previous assays have been activity based and underestimate TK1 in solid tumors.&nbspRead More

 

TK 210 ELISA is for Research Use Only. Not for Use in Diagnostic Procedures in the US.

Categories

Cancer-causing gene found in plasma may help predict outcomes for head and neck patients

by Eagle Biosciences


Trisha Wise-Draper, MD, PhD. (credit: Joe Fuqua, University of Cincinnati)


Researchers at the University of Cincinnati (UC) have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person’s immune system could be used to treat cancer or predict outcomes for patients.


(Source:  https://www.eurekalert.org/pub_releases/2016-02/uoca-cgf021516.php)